Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Salix, Progenics Report Results Of Phase 3 Trial Of Oral Methylnaltrexone

RELATED NEWS
Trade SLXP now with 
12/20/2011 7:25 AM ET

Salix Pharmaceuticals, Ltd. (SLXP: Quote) and Progenics Pharmaceuticals, Inc. (PGNX: Quote) announced the successful outcome of the Phase 3 trial to assess the efficacy and safety of oral methylnaltrexone for treating opioid-induced constipation in subjects with chronic, non-cancer pain.

The trial, evaluating three once-daily oral methylnaltrexone dosing regimens, showed highly statistically significant results for the primary endpoint in two of the three treatment arms versus placebo treatment arm. Both the 300 and 450 mg treatment arms demonstrated highly statistically significant improvements in rescue-free bowel movement, or RFBM, within 4 hours of administration over 28 days of dosing when compared to placebo treatment.

Also, the 300 and 450 mg treatment arms demonstrated highly statistically significant improvements in RFBM within 4 hours of administration following the first dose when compared to placebo treatment. Statistically significant efficacy was also seen in both the 300 and 450 mg treatment groups for the two key secondary efficacy endpoints.

Salix stated that overall, efficacy of oral methylnaltrexone in the study was comparable to that reported in clinical studies of subcutaneous methylnaltrexone in subjects with chronic, non-cancer pain. The overall observed safety profile seen in patients treated with oral methylnaltrexone was comparable to placebo in the study, the company added.

Register
To receive FREE breaking news email alerts for Salix Pharmaceuticals Ltd and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Design software maker Autodesk, Inc. (ADSK) Thursday reported a 30 percent decline in earnings from last year, hurt by lower revenue and weaker margins. The company's quarterly earnings per share, excluding items, came in below analysts' expectations as did its quarterly revenue. At the same time,... Struggling PC maker Dell Inc. said Thursday after the markets closed that its first quarter profit dropped 79% from last year, as revenue declined and margins deteriorated amid sluggish demand for personal computers. The company's quarterly earnings per share, excluding items, also came in way below analysts' expectations, but its quarterly revenue beat analysts' forecast. Cisco Systems, Inc., the world's largest computer networking gear maker, said Wednesday after the markets closed that its third quarter profit rose 14.5% from last year, helped by higher sales and a tax benefit. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly sales.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.